Harvard Bioscience, Inc. (HBIO)

US — Healthcare Sector

Peers: INFU PDEX LMAT UTMD MLSS POCI KRMD ANGO ICUI MMSI AKYA

Automate Your Wheel Strategy on HBIO

With Tiblio's Option Bot, you can configure your own wheel strategy including HBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol HBIO
Rev/Share 2.0727
Book/Share 0.3364
PB 1.2276
Debt/Equity 0.4874
CurrentRatio 0.8075
ROIC -1.8108

MktCap 18260258.0
FreeCF/Share 0.0133
PFCF 31.1608
PE -0.3137
Debt/Assets 0.0906
DivYield 0
ROE -1.1018

Rating C+
Score 2
Recommendation Sell
P/E Score 1
DCF Score 4
P/B Score 3
D/E Score 2

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Downgrade	HBIO	KeyBanc Capital Markets	Overweight	Sector Weight	--	--	April 9, 2025

News

Harvard Bioscience, Inc. (HBIO) Q1 2025 Earnings Call Transcript

HBIO
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q1 2025 Earnings Conference Call May 12, 2025 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller Jim Green - Chairman, President & CEO Mark Frost - Interim CFO Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the First Quarter 2025 Harvard Bioscience Inc Earnings Conference Call. All participants will be in a listen-only mode.

image for news Harvard Bioscience, Inc. (HBIO) Q1 2025 Earnings Call Transcript

Harvard Bioscience Announces First Quarter 2025 Financial Results

HBIO
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025.

image for news Harvard Bioscience Announces First Quarter 2025 Financial Results

Harvard Bioscience, Inc. (HBIO) Q4 2024 Earnings Call Transcript

HBIO
Published: March 12, 2025 by: Seeking Alpha
Sentiment: Neutral

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q4 2024 Results Conference Call March 12, 2025 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller Jim Green - Chairman, President & CEO Jennifer Cote - CFO & Treasurer Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Fourth Quarter 2024 Harvard Bioscience Earnings Conference Call. At this time, all participants are in listen-only mode.

image for news Harvard Bioscience, Inc. (HBIO) Q4 2024 Earnings Call Transcript

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

HBIO
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity

image for news Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET

HBIO
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

image for news Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET

About Harvard Bioscience, Inc. (HBIO)

IPO Date 2001-03-19
Website https://www.harvardbioscience.com
Industry Medical - Instruments & Supplies
CEO Mr. James W. Green
Employees 330

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.